Finance

Beta
Lists
HRMY:NASDAQ
Harmony Biosciences Holdings Inc
37,26 USD
+3,50%
(+1,26) 1D
36,00 USD
-3,38% (-1,26)
After hours
Closed: 2-июл., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HRMY...
Open
36,11 USD
High
37,40 USD
Low
35,92 USD
Mkt. cap
2,16 млд
Avg. vol.
819,92 миң
Volume
1,01 млн
P/E ratio
14,98
52-wk high
40,86 USD
52-wk low
25,52 USD
EPS
2,49 USD
Beta
0,94
Shares outstanding
57,89 млн
No. of employees
293
Open
36,11 USD
High
37,40 USD
Low
35,92 USD
Mkt. cap
2,16 млд
Avg. vol.
819,92 миң
Volume
1,01 млн
P/E ratio
14,98
52-wk high
40,86 USD
52-wk low
25,52 USD
EPS
2,49 USD
Beta
0,94
Shares outstanding
57,89 млн
No. of employees
293
News stories
From sources across the web
About Harmony Biosciences Holdings Inc
CEO-
Employees293
Founded2017
Headquarters-
SectorPharmaceutical industry
Websiteharmonybiosciences.com
Analyst ratings
Based on 7 analysts giving stock ratings to HRMY in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for HRMY in the last 3 months.
Highest
Current 37,26 USD
72,00 USD (+93,24%)
Average
47,57 USD (+27,67%)
Lowest
29,00 USD (-22,17%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Hoang
Deutsche Bank
Hold
Maintained
36,00 USD
-3,4%
06/30/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
55,00 USD
+47,6%
06/23/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
50,00 USD
+34,2%
06/11/2026
Danielle Brill
Truist Financial
Hold
Maintained
29,00 USD
-22,2%
05/08/2026
Ami Fadia
Needham
Buy
Reiterated
45,00 USD
+20,8%
05/07/2026
Jay Olson
Oppenheimer
Buy
Maintained
72,00 USD
+93,2%
04/22/2026
David Amsellem
Piper Sandler
Buy
Reiterated
46,00 USD
+23,5%
04/22/2026
Andreas Argyrides
Oppenheimer
Buy
Reiterated
62,00 USD
+66,4%
02/25/2026
So Youn Shim
UBS
Hold
Maintained
36,00 USD
-3,4%
02/25/2026
Jason Gerberry
Bank of America Securities
Sell
Reiterated
28,00 USD
-24,9%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
200,49 млн
239,46 млн
243,78 млн
215,39 млн
Cost of goods sold
38,15 млн
59,65 млн
68,54 млн
44,51 млн
Cost of revenue
38,15 млн
59,65 млн
68,54 млн
44,51 млн
Research and development expenses
50,16 млн
54,96 млн
49,93 млн
69,38 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
64,00 млн
59,36 млн
86,74 млн
64,20 млн
Operating expense
114,16 млн
114,32 млн
136,67 млн
133,58 млн
Total operating expenses
152,31 млн
173,97 млн
205,22 млн
178,10 млн
Operating income
48,18 млн
65,49 млн
38,56 млн
37,29 млн
Other non operating income
-193,00 миң
-106,00 миң
-105,00 миң
-127,00 миң
EBT including unusual items
49,64 млн
67,49 млн
40,76 млн
39,69 млн
EBT excluding unusual items
49,64 млн
67,49 млн
40,76 млн
39,69 млн
Income tax expense
9,86 млн
16,62 млн
18,27 млн
7,20 млн
Effective tax rate
19,87%
24,63%
44,83%
18,14%
Other operating expenses
-
-
-
-
Net income
39,78 млн
50,86 млн
22,49 млн
32,49 млн
Net profit margin
19,84%
21,24%
9,22%
15,08%
Earnings per share
0,92
1,08
0,57
0,79
Interest and investment income
5,30 млн
5,73 млн
5,85 млн
5,76 млн
Interest expense
-3,65 млн
-3,62 млн
-3,55 млн
-3,23 млн
Net interest expenses
1,65 млн
2,11 млн
2,31 млн
2,52 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
54,15 млн
71,46 млн
45,99 млн
43,26 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer